Hongbo Lu, Ph.D.

Hongbo Lu is the founding member of NEXTBio Capital, a newly launched biotech investment firm. Dr. Lu has 20+ years of healthcare investment experience in both public securities and private companies, including her previous tenure as Managing Partner of Vivo Capital, Managing Partner at Lilly Asia Ventures (LAV), and Managing Director at OrbiMed Advisors.  Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics (TPTX, acquired by BMS), Crown Bioscience Inc (6554.TT, acquired by JSR Life Sciences), Avedro (AVDR, acquired by Glaukos), Terns Pharmaceuticals (TERN), BlossomHill Therapeutics Inc, Zenas Biopharma, Createrna, Avistone Pharmaceuticals, and Echosens, among others. Dr. Lu also was extensively involved in the company incubations of ADARx Pharmaceuticals, RiboX Therapeutics, Visirna Inc., Ablaze Pharmaceuticals, Elpiscience, and Ronovo Surgical, and served as a founding director at Inception. Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and her scientific career in biotech start-ups in the Bay Area. Dr. Lu earned a Ph.D. (Bioengineering) from the University of Washington; an M.B.A. from the Haas School of Business at the University of California, Berkeley; and graduated with honors from Tsinghua University in China.